SODIUM ASCORBATE ENHANCEMENT OF CARBIDOPA-LEVODOPA METHYL-ESTER ANTI-TUMOR ACTIVITY AGAINST PIGMENTED B16-MELANOMA
- 1 January 1983
- journal article
- research article
- Vol. 43 (5) , 2047-2051
Abstract
The single and combined antitumor activity on B16 melanoma in female C57BL/6 .times. DBA/2F1 mice bearing s.c. tumors of sodium ascorbate, carbidopa-levodopa methyl ester, and dietary phenylalanine and tyrosine deficiency is reported. Groups of 15 mice were fed continuously one of 3 test diets both with and without sodium ascorbate (30 mg/ml) in the drinking water beginning 2 wk before inoculation of 106 melanoma cells. The test diets included the following amounts of tyrosine-phenylalanine: commercial, 1.09 and 0.64%; purified, 0.6 and 0.3%; and deficient, 0.08 and 0.04%. Drug-treated groups received daily injections of carbidopa (100 mg/kg) and levodopa methyl ester (1000 mg/kg) i.p. for 15 days beginning 1 day after tumor transplant. Tumor growth curves and median survival time were determined. Ascorbate stimulated tumor growth in the commercial diet group. In mice fed the purified diet, ascorbate inhibited growth in some tumors, while it had no effect on others. Ascorbate inhibited tumor growth in mice fed the deficient diet, which itself severely inhibited tumor growth, and in this group increased survival by 82%. Drug treatment had little effect on tumor growth and survival of mice fed the commercial diet, but it significantly decreased growth and moderately increased survival of mice fed the purified diet. The deficient diet enhanced drug activity and increased survival of tumor-bearing mice by 73%. Combined therapy had little effect in mice fed the commercial diet; however, mice fed the purified diet and receiving drug and ascorbate had smaller tumors and lived 55% longer. In mice fed the deficient diet, the combination retarded tumor growth and increased survival dramatically by 123%. Adding ascorbate and restricting tyrosine and phenylalanine in combination with levodopa methyl ester therapy may become an important strategy for treating malignant melanoma.This publication has 10 references indexed in Scilit:
- SELECTIVE TOXICITY OF 6-HYDROXYDOPAMINE AND ASCORBATE FOR HUMAN NEURO-BLASTOMA INVITRO - A MODEL FOR CLEARING MARROW PRIOR TO AUTOLOGOUS TRANSPLANT1982
- DNA DAMAGE AND SELECTIVE TOXICITY OF DOPA AND ASCORBATE - COPPER IN HUMAN-MELANOMA CELLS1982
- Ascorbic acid enhances the cytotoxic effect of 6-hydroxydopamine for human neuroblastoma cell linesNeuroscience Letters, 1981
- Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acidActa Dermato-Venereologica, 1981
- LEVODOPA AND DOPAMINE ANALOGS - DIHYDROXY AND TRIHYDROXYBENZYLAMINES AS NOVEL QUINOL ANTI-TUMOR AGENTS IN EXPERIMENTAL LEUKEMIA INVIVO1981
- Catecholamine Analogs as Potential Antitumor AgentsJournal of Pharmaceutical Sciences, 1979
- Selective Toxicity of 6-Hydroxydopa for Melanoma CellsJournal of Investigative Dermatology, 1979
- L-Dopa: Selective Toxicity for Melanoma Cells in VitroScience, 1977
- Effect of ascorbic acid on tumour growthBritish Journal of Cancer, 1977
- Enzyme defense against reactive oxygen derivatives. II. Erythrocytes and tumor cellsMolecular and Cellular Biochemistry, 1976